Mylan (NASDAQ:MYL) has been assigned a $43.00 price objective by investment analysts at Wells Fargo & Co in a research note issued to investors on Thursday. The firm currently has a “hold” rating on the stock. Wells Fargo & Co’s price target points to a potential downside of 6.34% from the stock’s previous close.

Other research analysts also recently issued reports about the stock. UBS Group reiterated a “buy” rating and set a $46.00 price objective on shares of Mylan in a research note on Thursday, October 5th. Instinet reiterated a “buy” rating and set a $37.00 price objective on shares of Mylan in a research note on Thursday, October 5th. Citigroup set a $42.00 price objective on shares of Mylan and gave the company a “buy” rating in a research note on Wednesday, October 4th. Mizuho reiterated a “buy” rating and set a $37.00 price objective on shares of Mylan in a research note on Wednesday, October 4th. Finally, ValuEngine upgraded shares of Mylan from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $44.19.

Mylan (MYL) traded down $0.60 on Thursday, reaching $45.91. 1,243,960 shares of the company were exchanged, compared to its average volume of 6,338,542. The firm has a market cap of $24,950.00, a price-to-earnings ratio of 27.66, a price-to-earnings-growth ratio of 1.49 and a beta of 1.38. Mylan has a 1-year low of $29.39 and a 1-year high of $47.25. The company has a debt-to-equity ratio of 1.05, a quick ratio of 0.95 and a current ratio of 1.46.

Mylan (NASDAQ:MYL) last released its quarterly earnings results on Monday, November 6th. The company reported $1.10 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.20 by ($0.10). The firm had revenue of $2.99 billion for the quarter, compared to analyst estimates of $3.09 billion. Mylan had a net margin of 7.28% and a return on equity of 20.63%. Mylan’s revenue for the quarter was down 2.3% on a year-over-year basis. During the same period in the previous year, the business posted $1.38 earnings per share. analysts forecast that Mylan will post 4.56 earnings per share for the current year.

In other news, CEO Heather M. Bresch sold 75,000 shares of the firm’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $45.00, for a total value of $3,375,000.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 0.69% of the company’s stock.

Large investors have recently modified their holdings of the stock. Canada Pension Plan Investment Board lifted its position in Mylan by 99.5% in the 3rd quarter. Canada Pension Plan Investment Board now owns 1,217,413 shares of the company’s stock valued at $38,189,000 after purchasing an additional 607,094 shares during the last quarter. FMR LLC lifted its position in Mylan by 19.8% in the 2nd quarter. FMR LLC now owns 813,267 shares of the company’s stock valued at $31,572,000 after purchasing an additional 134,258 shares during the last quarter. Toronto Dominion Bank lifted its position in Mylan by 28.2% in the 3rd quarter. Toronto Dominion Bank now owns 200,017 shares of the company’s stock valued at $6,274,000 after purchasing an additional 43,943 shares during the last quarter. Rhumbline Advisers lifted its position in Mylan by 7.2% in the 3rd quarter. Rhumbline Advisers now owns 791,463 shares of the company’s stock valued at $24,828,000 after purchasing an additional 53,154 shares during the last quarter. Finally, Nomura Holdings Inc. lifted its position in Mylan by 240.8% in the 2nd quarter. Nomura Holdings Inc. now owns 50,507 shares of the company’s stock valued at $1,961,000 after purchasing an additional 35,686 shares during the last quarter. Hedge funds and other institutional investors own 74.90% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Wells Fargo & Co Analysts Give Mylan (MYL) a $43.00 Price Target” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://www.thecerbatgem.com/2018/01/18/wells-fargo-co-reaffirms-market-perform-rating-for-mylan-myl.html.

Mylan Company Profile

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Analyst Recommendations for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.